GS010
AssetAlso LUMEVOQ
AAV2 gene therapy expressing ND4 targeting mitochondrial complex I to restore visual function.
- Stage
- Human trials
- Modality
- Gene therapy
- Target
- Oxidative phosphorylation
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Leber hereditary optic neuropathy
Human trials, gensight-biologics.com, 29 Sept 2026
In the full profile
- Targets and what it contains2
- Owner and partners2
- Evidence for its targets2
- Competitors1
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.